Innocare Pharma (PK)【INCPF】銘柄情報

Innocare Pharma Ltd (PK) (INCPF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

1.55

( - )

買値

1.27

売値

2.27

出来高

0.00 日の範囲 0.00

1.55 52 週間の範囲 3.26

時価総額

2.629B

前日終値

1.55

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 8,489,212

発行済株式数

1,695,928,424

配当利回り

PER

26.08

1 株当たり利益 (EPS)

0.43

歳入

2.52B

純利益

730.32M

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymph... InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China. 詳細を表示

セクター

Healthcare

業界

Pharmaceuticals

ウェブサイト

www.innocarepharma.com

本社

Beijing, China

設立

2026

Innocare Pharma Ltd (PK) is listed in the Healthcare sector of the その他OTC with ticker INCPF. The last closing price for Innocare Pharma (PK) was US$1.55. Over the last year, Innocare Pharma (PK) shares have traded in a share price range of US$ 1.55 to US$ 3.26.

Innocare Pharma (PK) currently has 1,695,928,424 shares in issue. The market capitalisation of Innocare Pharma (PK) is US$2.63 billion. Innocare Pharma (PK) has a price to earnings ratio (PE ratio) of 26.08.

Zenas Biopharma Acquires Rights to Three Autoimmune Drug Candidates from InnoCare

Zenas Biopharma (NASDAQ:ZBIO) has entered into a licensing agreement with InnoCare Pharma (USOTC:INCPF), securing global rights to three...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	1.55	1.55	1.55	0	0	CS
26	-0.5	-24.3902439024	2.05	2.05	1.55	143	1.55	CS
52	-1.71	-52.4539877301	3.26	3.26	1.55	100	1.83818182	CS
156	-1.71	-52.4539877301	3.26	3.26	1.55	79	1.83818182	CS
260	-2.15	-58.1081081081	3.7	3.72	1.55	273	3.26712871	CS